Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2020
August 2020, Vol 11, No 4 | Payers' Perspectives in Oncology: ASCO 2020 Highlights
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Tumor-Infiltrating Lymphocyte Therapy Induces Responses Across Wide Range of Patients with Advanced Melanoma
By
Wayne Kuznar
Emerging Therapies
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
A single infusion of the investigational agent lifileucel—an immunotherapy using cryopreserved autologous tumor-infiltrating lymphocytes (TIL)—induced responses in more than 33% of patients with advanced melanoma whose disease progressed with multiple previous therapies, including PD-1 and BRAF/MEK inhibitors.
Read More
Capmatinib Shows Activity in MET-Amplified Non–Small-Cell Lung Cancer
By
Wayne Kuznar
Lung Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Capmatinib (Tabrecta), an oral kinase inhibitor, has shown clinical activity in patients with high-level
MET
-amplified advanced non–small-cell lung cancer (NSCLC), according to new data presented at the ASCO 2020 virtual annual meeting.
Read More
Durvalumab plus Chemotherapy New Standard of Care for Extensive-Stage Small-Cell Lung Cancer
By
Phoebe Starr
Lung Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Updated results of the phase 3 CASPIAN clinical trial continue to show that durvalumab (Imfinzi) added to standard chemotherapy improves overall survival (OS) for patients with treatment-naïve extensive-stage small-cell lung cancer (ES-SCLC), according to a presentation at the ASCO 2020 virtual annual meeting.
Read More
The Value of Some Cancer Drugs Changes Substantially After Their Approval
By
Chase Doyle
Value-Based Care
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
An analysis of the Value Framework of the American Society of Clinical Oncology (ASCO) shows that the Net Health Benefit score of cancer drugs continues to evolve over time after their FDA approval, based on data presented at the ASCO 2020 virtual annual meeting.
Read More
Germline Alterations Analysis Has Actionable Value in Selecting Targetable Treatments for Patients with Advanced Cancer
By
Chase Doyle
Value-Based Care
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
New research highlights the importance of germline analysis in the identification of germline alterations for cancer treatment.
Read More
Cemiplimab Cost-Effective for Advanced Cutaneous Squamous-Cell Carcinoma
By
Chase Doyle
Value-Based Care
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Cemiplimab-rwlc (Libtayo), a PD-1 inhibitor, has transformed the treatment of advanced cutaneous squamous-cell carcinoma (CSCC), significantly extending survival for patients.
Read More
Clinical Decision Support Helps Compliance with Evidence-Based Pathways
By
Chase Doyle
Value-Based Care
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
As the complexity of cancer care continues to evolve, adhering to evidence-based treatment guidelines is a growing challenge for oncologists.
Read More
Cancer Drugs Show Promise as Potential Treatment for COVID-19
COVID-19
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Nationally renowned oncologist Maurie Markman, MD, President of Medicine and Science at Cancer Treatment Centers of America, led a panel of experts in discussing how existing anticancer agents, such as kinase inhibitors and the corticosteroid dexamethasone, may be used for the treatment of patients with COVID-19 in a July webinar of the Association for Value-Based Cancer Care (AVBCC) on COVID-19.
Read More
Adjuvant Osimertinib a Practice-Changing Treatment in Early-Stage NSCLC with EGFR Mutation
By
Wayne Kuznar
Lung Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Treatment with osimertinib (Tagrisso) in the adjuvant setting significantly improves disease-free survival (DFS) in patients with localized non–small-cell lung cancer (NSCLC) with an
EGFR
mutation, according to results presented by Roy S. Herbst, MD, PhD, FACP, FASCO, Chief of Medical Oncology, Yale Cancer Center, New Haven, CT, at the ASCO 2020 virtual annual meeting.
Read More
Oral Relugolix Equals Standard ADT, Slashes Cardiac Events in Patients with Advanced Prostate Cancer
By
Phoebe Starr
Prostate Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Oral relugolix given daily is superior to standard androgen-deprivation therapy (ADT) with leuprolide (Lupron) in men with advanced prostate cancer, according to the results of the phase 3 HERO study, which were reported at the ASCO 2020 virtual annual meeting and published online before the meeting.
Read More
Page 3 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma